NEW DRUG DISCOVERY PROJECT

新药发现项目

• 批准号: 3874498
• 负责人: B S KRAMER
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3874498
• 关键词: 5 fluorouridine; antileukemic agent; antineoplastics; antitumor antibody; athymic mouse; bronchogenic carcinoma; carcinoma; chronic leukemia; cis platinum compound; clinical trials; colon neoplasms; dipyridamole; drug design /synthesis /production; drug screening /evaluation; etoposide; fluorine; fluorouracil; human subject; human tissue; immunotherapy; leucovorin; lung neoplasms; lymphocytic leukemia; methotrexate; monoclonal antibody; mycosis fungoides lymphoma; neoplasm /cancer; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; neoplastic cell; pyridine; yttrium

The primary goal of this group is to identify new agents of potential clinical use in treating solid tumors. A major effort over the past 2 years has been the use of an in vitro assay which may be helpful as a preclinical screening model for antitumor agents. The model has been used to predict the clinical activity of 7 chemotherapeutic agents against 11 human colorectal carcinoma cell lines which have been developed in this branch. Using the model, we have shown that leucovorin enhances the in vitro cytotoxicity of the fluoropyridines versus our panel of colorectal cell lines. A study was also performed to detect possible synergy between etoposide and cisplatin in a panel of 8 human bronchogenic carcinoma cell lines. Extensive analysis revealed no in vitro synergy, a finding at variance with standard feeling. Schedule dependent drug interaction has been documented between methotrexate and 5-fluorouracil. Persantine has been shown to enhance the cytotoxicity of 10-EDAM in human lung cancer cell lines. Clinical trails are planned to explore this. At present, we are involved in several trials of new experimental therapeutic agents: a radiolabeled monoclonal antibody (90yttrium-T101) in mycosis fungoides and chronic lymphocytic leukemia; 4-ipomeanol in lung cancer and a Phase I trial of hepsulfam.

该小组的主要目标是确定具有潜力的新代理人 临床用于治疗实体瘤。 过去2年的重大努力 多年来一直使用体外测定，这可能有助于 抗肿瘤药物的临床前筛选模型。 该模型已被使用 预测 7 种化疗药物相对于 11 种化疗药物的临床活性 人结直肠癌细胞系 分支。 使用该模型，我们已经证明亚叶酸可以增强体内 氟吡啶与我们的结直肠组的体外细胞毒性 细胞系。 还进行了一项研究来检测之间可能的协同作用 依托泊苷和顺铂在一组 8 个人支气管癌细胞中的分布 线。 广泛的分析表明没有体外协同作用，一项发现 与标准感觉的差异。 时间表依赖性药物相互作用 甲氨蝶呤和 5-氟尿嘧啶之间有记录。 佩尔桑汀有 已被证明可增强 10-EDAM 对人肺癌细胞的细胞毒性 线。 计划进行临床试验来探索这一点。 目前，我们正在参与多项新实验的尝试 治疗剂：放射性标记的单克隆抗体 (90yttrium-T101) 蕈样肉芽肿和慢性淋巴细胞白血病； 4-ipomeanol 在肺中 癌症和 Hepsulfam 的 I 期试验。